Research also identified a rationally-defined consortium of human commensal bacteria (VE800) that robustly induces IFNy+ CD8+ T cells and enhances antitumor immunity . Vedanta’s clinical candidate VE800 is expected to enter clinical studies in 2019 in combination with Bristol-Myers Squibb’s checkpoint inhibitor OPDIVO® (nivolumab)
24 January, 2019
Two in five parents are exposed to negative messages about vaccines on social media and this rises to one in two among parents of under 5s. Across a range of vaccines including MMR, HPV, and Flu, fear of side effects was the most common reason for choosing not to vaccinate.
24 January, 2019
Alzheimer’s-affected brains are riddled with so-called amyloid plaques: protein aggregates consisting mainly of amyloid-ß. However, this amyloid-ß is a fragment produced from a precursor protein whose normal function has remained enigmatic for decades. A team of scientists at VIB and KU Leuven led by professors Joris de Wit and Bart De Strooper has now uncovered that this amyloid precursor protein modulates neuronal signal transmission through binding to a specific receptor. Modulating this receptor could potentially help treat Alzheimer’s or other brain diseases. The results are published in Science.
11 January, 2019